APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Anti-Diabetic Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Oral Anti-Diabetic Drug Market Outlook and Growth Opportunities 2026

2 January 2026194 pages

Choose your research edition.

Industry ResearchOral Anti-Diabetic Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Anti-Diabetic Drug Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Oral Anti-Diabetic Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Anti-Diabetic Drug Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Anti-Diabetic Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Oral Anti-Diabetic Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Oral Anti-Diabetic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oral Anti-Diabetic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral Anti-Diabetic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Oral Anti-Diabetic Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Oral Anti-Diabetic Drug market include Astellas, Biocon, Boehringer Ingelheim, Bristol Myers Squibb, Merck And Co., AstraZeneca, Pfizer, Eli Lilly and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oral Anti-Diabetic Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oral Anti-Diabetic Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oral Anti-Diabetic Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oral Anti-Diabetic Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Oral Anti-Diabetic Drug Segment by Company

Astellas

Biocon

Boehringer Ingelheim

Bristol Myers Squibb

Merck And Co.

AstraZeneca

Pfizer

Eli Lilly

Novartis

Sanofi

Takeda

Abbott

Janssen Pharmaceuticals

Oral Anti-Diabetic Drug Segment by Type

Gliclazide

Glimepiride

Glyburide

Others

Oral Anti-Diabetic Drug Segment by Application

Hospital

Research Institual

Oral Anti-Diabetic Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Oral Anti-Diabetic Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Oral Anti-Diabetic Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oral Anti-Diabetic Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Oral Anti-Diabetic Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Anti-Diabetic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Anti-Diabetic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Anti-Diabetic Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oral Anti-Diabetic Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oral Anti-Diabetic Drug industry.

Chapter 3: Detailed analysis of Oral Anti-Diabetic Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Oral Anti-Diabetic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Oral Anti-Diabetic Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oral Anti-Diabetic Drug Industry Trends Table 2. Oral Anti-Diabetic Drug Industry Drivers Table 3. Oral Anti-Diabetic Drug Industry Opportunities and Challenges Table 4. Oral Anti-Diabetic Drug Industry Restraints Table 5. Global Oral Anti-Diabetic Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oral Anti-Diabetic Drug Revenue Share by Company (2021-2026) Table 7. Global Oral Anti-Diabetic Drug Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Oral Anti-Diabetic Drug Sales Volume Share by Company (2021-2026) Table 9. Global Oral Anti-Diabetic Drug Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Oral Anti-Diabetic Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Oral Anti-Diabetic Drug Key Company Manufacturing Base & Headquarters Table 12. Global Oral Anti-Diabetic Drug Company, Product Type & Application Table 13. Global Oral Anti-Diabetic Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Oral Anti-Diabetic Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Gliclazide Table 18. Significant Companies of Glimepiride Table 19. Significant Companies of Glyburide Table 20. Significant Companies of Others Table 21. Global Oral Anti-Diabetic Drug Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 22. Global Oral Anti-Diabetic Drug Sales Volume by Type (2021-2026) & (Tons) Table 23. Global Oral Anti-Diabetic Drug Sales Volume by Type (2027-2032) & (Tons) Table 24. Global Oral Anti-Diabetic Drug Sales Volume Share by Type (2021-2026) Table 25. Global Oral Anti-Diabetic Drug Sales Volume Share by Type (2027-2032) Table 26. Global Oral Anti-Diabetic Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Oral Anti-Diabetic Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Oral Anti-Diabetic Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Oral Anti-Diabetic Drug Sales Value Share by Type (2021-2026) Table 30. Global Oral Anti-Diabetic Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Research Institual Table 33. Global Oral Anti-Diabetic Drug Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 34. Global Oral Anti-Diabetic Drug Sales Volume by Application (2021-2026) & (Tons) Table 35. Global Oral Anti-Diabetic Drug Sales Volume by Application (2027-2032) & (Tons) Table 36. Global Oral Anti-Diabetic Drug Sales Volume Share by Application (2021-2026) Table 37. Global Oral Anti-Diabetic Drug Sales Volume Share by Application (2027-2032) Table 38. Global Oral Anti-Diabetic Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Oral Anti-Diabetic Drug Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Oral Anti-Diabetic Drug Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Oral Anti-Diabetic Drug Sales Value Share by Application (2021-2026) Table 42. Global Oral Anti-Diabetic Drug Sales Value Share by Application (2027-2032) Table 43. Global Oral Anti-Diabetic Drug Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 44. Global Oral Anti-Diabetic Drug Sales by Region (2021-2026) & (Tons) Table 45. Global Oral Anti-Diabetic Drug Sales Market Share by Region (2021-2026) Table 46. Global Oral Anti-Diabetic Drug Sales by Region (2027-2032) & (Tons) Table 47. Global Oral Anti-Diabetic Drug Sales Market Share by Region (2027-2032) Table 48. Global Oral Anti-Diabetic Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Oral Anti-Diabetic Drug Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Oral Anti-Diabetic Drug Sales Value Share by Region (2021-2026) Table 51. Global Oral Anti-Diabetic Drug Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Oral Anti-Diabetic Drug Sales Value Share by Region (2027-2032) Table 53. Global Oral Anti-Diabetic Drug Market Average Price (US$/Ton) by Region (2021-2026) Table 54. Global Oral Anti-Diabetic Drug Market Average Price (US$/Ton) by Region (2027-2032) Table 55. Global Oral Anti-Diabetic Drug Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 56. Global Oral Anti-Diabetic Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Oral Anti-Diabetic Drug Sales by Country (2021-2026) & (Tons) Table 58. Global Oral Anti-Diabetic Drug Sales Market Share by Country (2021-2026) Table 59. Global Oral Anti-Diabetic Drug Sales by Country (2027-2032) & (Tons) Table 60. Global Oral Anti-Diabetic Drug Sales Market Share by Country (2027-2032) Table 61. Global Oral Anti-Diabetic Drug Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Oral Anti-Diabetic Drug Sales Value Market Share by Country (2021-2026) Table 63. Global Oral Anti-Diabetic Drug Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Oral Anti-Diabetic Drug Sales Value Market Share by Country (2027-2032) Table 65. Astellas Company Information Table 66. Astellas Business Overview Table 67. Astellas Oral Anti-Diabetic Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 68. Astellas Oral Anti-Diabetic Drug Product Portfolio Table 69. Astellas Recent Development Table 70. Biocon Company Information Table 71. Biocon Business Overview Table 72. Biocon Oral Anti-Diabetic Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 73. Biocon Oral Anti-Diabetic Drug Product Portfolio Table 74. Biocon Recent Development Table 75. Boehringer Ingelheim Company Information Table 76. Boehringer Ingelheim Business Overview Table 77. Boehringer Ingelheim Oral Anti-Diabetic Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 78. Boehringer Ingelheim Oral Anti-Diabetic Drug Product Portfolio Table 79. Boehringer Ingelheim Recent Development Table 80. Bristol Myers Squibb Company Information Table 81. Bristol Myers Squibb Business Overview Table 82. Bristol Myers Squibb Oral Anti-Diabetic Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 83. Bristol Myers Squibb Oral Anti-Diabetic Drug Product Portfolio Table 84. Bristol Myers Squibb Recent Development Table 85. Merck And Co. Company Information Table 86. Merck And Co. Business Overview Table 87. Merck And Co. Oral Anti-Diabetic Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 88. Merck And Co. Oral Anti-Diabetic Drug Product Portfolio Table 89. Merck And Co. Recent Development Table 90. AstraZeneca Company Information Table 91. AstraZeneca Business Overview Table 92. AstraZeneca Oral Anti-Diabetic Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 93. AstraZeneca Oral Anti-Diabetic Drug Product Portfolio Table 94. AstraZeneca Recent Development Table 95. Pfizer Company Information Table 96. Pfizer Business Overview Table 97. Pfizer Oral Anti-Diabetic Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 98. Pfizer Oral Anti-Diabetic Drug Product Portfolio Table 99. Pfizer Recent Development Table 100. Eli Lilly Company Information Table 101. Eli Lilly Business Overview Table 102. Eli Lilly Oral Anti-Diabetic Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 103. Eli Lilly Oral Anti-Diabetic Drug Product Portfolio Table 104. Eli Lilly Recent Development Table 105. Novartis Company Information Table 106. Novartis Business Overview Table 107. Novartis Oral Anti-Diabetic Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 108. Novartis Oral Anti-Diabetic Drug Product Portfolio Table 109. Novartis Recent Development Table 110. Sanofi Company Information Table 111. Sanofi Business Overview Table 112. Sanofi Oral Anti-Diabetic Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 113. Sanofi Oral Anti-Diabetic Drug Product Portfolio Table 114. Sanofi Recent Development Table 115. Takeda Company Information Table 116. Takeda Business Overview Table 117. Takeda Oral Anti-Diabetic Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 118. Takeda Oral Anti-Diabetic Drug Product Portfolio Table 119. Takeda Recent Development Table 120. Abbott Company Information Table 121. Abbott Business Overview Table 122. Abbott Oral Anti-Diabetic Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 123. Abbott Oral Anti-Diabetic Drug Product Portfolio Table 124. Abbott Recent Development Table 125. Janssen Pharmaceuticals Company Information Table 126. Janssen Pharmaceuticals Business Overview Table 127. Janssen Pharmaceuticals Oral Anti-Diabetic Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 128. Janssen Pharmaceuticals Oral Anti-Diabetic Drug Product Portfolio Table 129. Janssen Pharmaceuticals Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Oral Anti-Diabetic Drug Distributors List Table 133. Oral Anti-Diabetic Drug Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Oral Anti-Diabetic Drug Product Image Figure 2. Global Oral Anti-Diabetic Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Anti-Diabetic Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Oral Anti-Diabetic Drug Sales (2021-2032) & (Tons) Figure 5. Global Oral Anti-Diabetic Drug Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Oral Anti-Diabetic Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Gliclazide Image Figure 10. Glimepiride Image Figure 11. Glyburide Image Figure 12. Others Image Figure 13. Global Oral Anti-Diabetic Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 14. Global Oral Anti-Diabetic Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Oral Anti-Diabetic Drug Sales Volume Share by Type (2021-2032) Figure 16. Global Oral Anti-Diabetic Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Oral Anti-Diabetic Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Oral Anti-Diabetic Drug Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Research Institual Image Figure 21. Global Oral Anti-Diabetic Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 22. Global Oral Anti-Diabetic Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Oral Anti-Diabetic Drug Sales Volume Share by Application (2021-2032) Figure 24. Global Oral Anti-Diabetic Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Oral Anti-Diabetic Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Oral Anti-Diabetic Drug Sales Value Share by Application (2021-2032) Figure 27. Global Oral Anti-Diabetic Drug Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 28. Global Oral Anti-Diabetic Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Oral Anti-Diabetic Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Oral Anti-Diabetic Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Oral Anti-Diabetic Drug Sales Value (2021-2032) & (US$ Million) Figure 32. North America Oral Anti-Diabetic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Oral Anti-Diabetic Drug Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Oral Anti-Diabetic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Oral Anti-Diabetic Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Oral Anti-Diabetic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Oral Anti-Diabetic Drug Sales Value (2021-2032) & (US$ Million) Figure 38. South America Oral Anti-Diabetic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Oral Anti-Diabetic Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Oral Anti-Diabetic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Oral Anti-Diabetic Drug Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Oral Anti-Diabetic Drug Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Gliclazide
  • Glimepiride
  • Glyburide
  • Others
Applications
  • Hospital
  • Research Institual
Companies covered
  • Astellas
  • Biocon
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Merck And Co.
  • AstraZeneca
  • Pfizer
  • Eli Lilly
  • Novartis
  • Sanofi
  • Takeda
  • Abbott
  • Janssen Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Oral Anti-Diabetic Drug Sales Value (2021-2032)
  4. 1.2.2 Global Oral Anti-Diabetic Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Oral Anti-Diabetic Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Oral Anti-Diabetic Drug Market Dynamics
  1. 2.1 Oral Anti-Diabetic Drug Industry Trends
  2. 2.2 Oral Anti-Diabetic Drug Industry Drivers
  3. 2.3 Oral Anti-Diabetic Drug Industry Opportunities and Challenges
  4. 2.4 Oral Anti-Diabetic Drug Industry Restraints
3 Oral Anti-Diabetic Drug Market by Company
  1. 3.1 Global Oral Anti-Diabetic Drug Company Revenue Ranking in 2025
  2. 3.2 Global Oral Anti-Diabetic Drug Revenue by Company (2021-2026)
  3. 3.3 Global Oral Anti-Diabetic Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Oral Anti-Diabetic Drug Average Price by Company (2021-2026)
  5. 3.5 Global Oral Anti-Diabetic Drug Company Ranking (2024-2026)
  6. 3.6 Global Oral Anti-Diabetic Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Oral Anti-Diabetic Drug Company Product Type and Application
  8. 3.8 Global Oral Anti-Diabetic Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Oral Anti-Diabetic Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Oral Anti-Diabetic Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Oral Anti-Diabetic Drug Market by Type
  1. 4.1 Oral Anti-Diabetic Drug Type Introduction
  2. 4.1.1 Gliclazide
  3. 4.1.2 Glimepiride
  4. 4.1.3 Glyburide
  5. 4.1.4 Others
  6. 4.2 Global Oral Anti-Diabetic Drug Sales Volume by Type
  7. 4.2.1 Global Oral Anti-Diabetic Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Oral Anti-Diabetic Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Oral Anti-Diabetic Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Oral Anti-Diabetic Drug Sales Value by Type
  11. 4.3.1 Global Oral Anti-Diabetic Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Oral Anti-Diabetic Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global Oral Anti-Diabetic Drug Sales Value Share by Type (2021-2032)
5 Oral Anti-Diabetic Drug Market by Application
  1. 5.1 Oral Anti-Diabetic Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Research Institual
  4. 5.2 Global Oral Anti-Diabetic Drug Sales Volume by Application
  5. 5.2.1 Global Oral Anti-Diabetic Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Oral Anti-Diabetic Drug Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Oral Anti-Diabetic Drug Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Oral Anti-Diabetic Drug Sales Value by Application
  9. 5.3.1 Global Oral Anti-Diabetic Drug Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Oral Anti-Diabetic Drug Sales Value by Application (2021-2032)
  11. 5.3.3 Global Oral Anti-Diabetic Drug Sales Value Share by Application (2021-2032)
6 Oral Anti-Diabetic Drug Regional Sales and Value Analysis
  1. 6.1 Global Oral Anti-Diabetic Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oral Anti-Diabetic Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Oral Anti-Diabetic Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Oral Anti-Diabetic Drug Sales by Region (2027-2032)
  5. 6.3 Global Oral Anti-Diabetic Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Oral Anti-Diabetic Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Oral Anti-Diabetic Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Oral Anti-Diabetic Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Oral Anti-Diabetic Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Oral Anti-Diabetic Drug Sales Value (2021-2032)
  12. 6.6.2 North America Oral Anti-Diabetic Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Oral Anti-Diabetic Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Oral Anti-Diabetic Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Oral Anti-Diabetic Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Oral Anti-Diabetic Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Oral Anti-Diabetic Drug Sales Value (2021-2032)
  21. 6.9.2 South America Oral Anti-Diabetic Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Oral Anti-Diabetic Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Oral Anti-Diabetic Drug Sales Value Share by Country, 2025 VS 2032
7 Oral Anti-Diabetic Drug Country-level Sales and Value Analysis
  1. 7.1 Global Oral Anti-Diabetic Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oral Anti-Diabetic Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Oral Anti-Diabetic Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Oral Anti-Diabetic Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Oral Anti-Diabetic Drug Sales by Country (2027-2032)
  6. 7.4 Global Oral Anti-Diabetic Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Oral Anti-Diabetic Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Oral Anti-Diabetic Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Oral Anti-Diabetic Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Oral Anti-Diabetic Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Oral Anti-Diabetic Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Astellas
  2. 8.1.1 Astellas Company Information
  3. 8.1.2 Astellas Business Overview
  4. 8.1.3 Astellas Oral Anti-Diabetic Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Astellas Oral Anti-Diabetic Drug Product Portfolio
  6. 8.1.5 Astellas Recent Developments
  7. 8.2 Biocon
  8. 8.2.1 Biocon Company Information
  9. 8.2.2 Biocon Business Overview
  10. 8.2.3 Biocon Oral Anti-Diabetic Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Biocon Oral Anti-Diabetic Drug Product Portfolio
  12. 8.2.5 Biocon Recent Developments
  13. 8.3 Boehringer Ingelheim
  14. 8.3.1 Boehringer Ingelheim Company Information
  15. 8.3.2 Boehringer Ingelheim Business Overview
  16. 8.3.3 Boehringer Ingelheim Oral Anti-Diabetic Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer Ingelheim Oral Anti-Diabetic Drug Product Portfolio
  18. 8.3.5 Boehringer Ingelheim Recent Developments
  19. 8.4 Bristol Myers Squibb
  20. 8.4.1 Bristol Myers Squibb Company Information
  21. 8.4.2 Bristol Myers Squibb Business Overview
  22. 8.4.3 Bristol Myers Squibb Oral Anti-Diabetic Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bristol Myers Squibb Oral Anti-Diabetic Drug Product Portfolio
  24. 8.4.5 Bristol Myers Squibb Recent Developments
  25. 8.5 Merck And Co.
  26. 8.5.1 Merck And Co. Company Information
  27. 8.5.2 Merck And Co. Business Overview
  28. 8.5.3 Merck And Co. Oral Anti-Diabetic Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck And Co. Oral Anti-Diabetic Drug Product Portfolio
  30. 8.5.5 Merck And Co. Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Oral Anti-Diabetic Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Oral Anti-Diabetic Drug Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Oral Anti-Diabetic Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Oral Anti-Diabetic Drug Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Oral Anti-Diabetic Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Oral Anti-Diabetic Drug Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Novartis
  50. 8.9.1 Novartis Company Information
  51. 8.9.2 Novartis Business Overview
  52. 8.9.3 Novartis Oral Anti-Diabetic Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Novartis Oral Anti-Diabetic Drug Product Portfolio
  54. 8.9.5 Novartis Recent Developments
  55. 8.10 Sanofi
  56. 8.10.1 Sanofi Company Information
  57. 8.10.2 Sanofi Business Overview
  58. 8.10.3 Sanofi Oral Anti-Diabetic Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Oral Anti-Diabetic Drug Product Portfolio
  60. 8.10.5 Sanofi Recent Developments
  61. 8.11 Takeda
  62. 8.11.1 Takeda Company Information
  63. 8.11.2 Takeda Business Overview
  64. 8.11.3 Takeda Oral Anti-Diabetic Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Takeda Oral Anti-Diabetic Drug Product Portfolio
  66. 8.11.5 Takeda Recent Developments
  67. 8.12 Abbott
  68. 8.12.1 Abbott Company Information
  69. 8.12.2 Abbott Business Overview
  70. 8.12.3 Abbott Oral Anti-Diabetic Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Abbott Oral Anti-Diabetic Drug Product Portfolio
  72. 8.12.5 Abbott Recent Developments
  73. 8.13 Janssen Pharmaceuticals
  74. 8.13.1 Janssen Pharmaceuticals Company Information
  75. 8.13.2 Janssen Pharmaceuticals Business Overview
  76. 8.13.3 Janssen Pharmaceuticals Oral Anti-Diabetic Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Janssen Pharmaceuticals Oral Anti-Diabetic Drug Product Portfolio
  78. 8.13.5 Janssen Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oral Anti-Diabetic Drug Value Chain Analysis
  2. 9.1.1 Oral Anti-Diabetic Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oral Anti-Diabetic Drug Sales Mode & Process
  6. 9.2 Oral Anti-Diabetic Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oral Anti-Diabetic Drug Distributors
  9. 9.2.3 Oral Anti-Diabetic Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst